IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
89.52 USD
+2.01 (+2.3%)
89.52 USD
0 (0%)
Taking everything into account, IRMD scores 7 out of 10 in our fundamental rating. IRMD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD is not valued too expensively and it also shows a decent growth rate. These ratings could make IRMD a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
IRMD had a positive operating cash flow in the past year.
IRMD had positive earnings in each of the past 5 years.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of IRMD (18.47%) is better than 98.40% of its industry peers.
The Return On Equity of IRMD (21.54%) is better than 94.15% of its industry peers.
IRMD's Return On Invested Capital of 19.30% is amongst the best of the industry. IRMD outperforms 97.34% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.98%.
The last Return On Invested Capital (19.30%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.31%, IRMD belongs to the top of the industry, outperforming 95.21% of the companies in the same industry.
IRMD's Profit Margin has been stable in the last couple of years.
The Operating Margin of IRMD (30.87%) is better than 97.87% of its industry peers.
In the last couple of years the Operating Margin of IRMD has grown nicely.
IRMD's Gross Margin of 77.07% is amongst the best of the industry. IRMD outperforms 89.36% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
IRMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IRMD has more shares outstanding
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IRMD has an Altman-Z score of 43.78. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
IRMD's Altman-Z score of 43.78 is amongst the best of the industry. IRMD outperforms 99.47% of its industry peers.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 43.78 |
ROIC/WACC2.21
WACC8.74%
2.3 Liquidity
A Current Ratio of 6.64 indicates that IRMD has no problem at all paying its short term obligations.
IRMD has a Current ratio of 6.64. This is amongst the best in the industry. IRMD outperforms 84.57% of its industry peers.
IRMD has a Quick Ratio of 5.72. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD has a better Quick ratio (5.72) than 85.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.75% over the past year.
Measured over the past years, IRMD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.92% on average per year.
The Revenue has grown by 12.91% in the past year. This is quite good.
IRMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.71% yearly.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
3.2 Future
The Earnings Per Share is expected to grow by 9.26% on average over the next years. This is quite good.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.97% yearly.
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 49.19, the valuation of IRMD can be described as expensive.
69.15% of the companies in the same industry are more expensive than IRMD, based on the Price/Earnings ratio.
IRMD is valuated expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
IRMD is valuated quite expensively with a Price/Forward Earnings ratio of 41.89.
IRMD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 70.74% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, IRMD is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.19 | ||
| Fwd PE | 41.89 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 67.55% of the companies are valued more expensively.
IRMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 81.63 | ||
| EV/EBITDA | 40.9 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)3.93
PEG (5Y)3.53
EPS Next 2Y13.8%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
With a yearly dividend of 0.80%, IRMD is not a good candidate for dividend investing.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.69. IRMD pays more dividend than 92.02% of the companies in the same industry.
With a Dividend Yield of 0.80, IRMD pays less dividend than the S&P500 average, which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
5.2 History
IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
IRMD pays out 39.59% of its income as dividend. This is a sustainable payout ratio.
DP39.59%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
89.52
+2.01 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change-1.64%
Ins Owners36.81%
Ins Owner Change-5.49%
Market Cap1.14B
Revenue(TTM)80.51M
Net Income(TTM)21.18M
Analysts82.5
Price Target76.5 (-14.54%)
Short Float %2.49%
Short Ratio3.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)2.04%
PT rev (3m)2.04%
EPS NQ rev (1m)2.13%
EPS NQ rev (3m)-2.04%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)4.9%
Revenue NQ rev (1m)5.37%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.19 | ||
| Fwd PE | 41.89 | ||
| P/S | 14.14 | ||
| P/FCF | 81.63 | ||
| P/OCF | 45.53 | ||
| P/B | 11.58 | ||
| P/tB | 11.99 | ||
| EV/EBITDA | 40.9 |
EPS(TTM)1.82
EY2.03%
EPS(NY)2.14
Fwd EY2.39%
FCF(TTM)1.1
FCFY1.23%
OCF(TTM)1.97
OCFY2.2%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)3.93
PEG (5Y)3.53
Graham Number17.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROCE | 24.38% | ||
| ROIC | 19.3% | ||
| ROICexc | 43.34% | ||
| ROICexgc | 46.82% | ||
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% | ||
| FCFM | 17.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1128.47% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.82% | ||
| Profit Quality | 65.85% | ||
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 | ||
| Altman-Z | 43.78 |
F-Score4
WACC8.74%
ROIC/WACC2.21
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.31%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y98.66%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
What is the valuation status of IRADIMED CORP (IRMD) stock?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
How financially healthy is IRADIMED CORP?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.
Is the dividend of IRADIMED CORP sustainable?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 39.59%.